SpringWorks Therapeutics Inc

NASDAQ:SWTX   10:52:23 AM EDT
50.22
-1.76 (-3.39%)
Strategic Combinations, Regulatory, Earnings Announcements

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

Published: 12/10/2021 11:41 GMT
SpringWorks Therapeutics Inc (SWTX) - Springworks Therapeutics Announces Clinical Collaboration With Abbvie to Evaluate Nirogacestat in Combination With Abbv-383 in Patients With Relapsed Or Refractory Multiple Myeloma.
Springworks Therapeutics - Under Agreement, Abbvie Will Sponsor and Conduct Phase 1b Study and Will Assume All Costs Associated With Study.
Springworks Therapeutics - Abbvie, Co to Form Joint Steering Committee to Manage Clinical Study, Which is Expected to Commence in H1 of 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.83

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.85

More details on our Analysts Page.